Avance Clinical and Medidata Celebrate Strategic Partnership and Inhouse Expert Accreditation Milestones
ADELAIDE, AUS, Feb 26, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs, and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical continues to celebrate their strategic partnership with Medidata, and the accreditation of seven Medidata inhouse experts.
The two organizations have been working together to deliver world-class clinical research services to Avance Clinical's biotech customers via the Medidata Rave Clinical Cloud™.
Avance Clinical, Chief Strategy Officer, Ben Edwards said "We look forward to many more years working with Medidata as we continue to grow the business and support the development needs of our clients."
Mr Edwin Ng, Senior Vice President, General Manager for Medidata APAC, said, "We are pleased to be supporting Avance Clinical's exceptional growth in Australia. Avance Clinical accreditation signifies the importance of Medidata's portfolio of products in ensuring the success of our partners' programs, and our continued commitment to helping our partners streamline and enhance the clinical research process."
Avance Clinical, Director Business Development Operations, Sandrien Louwaars said, "The Medidata Rave Clinical Cloud™ is a quality- and efficiency-focused unified platform that helps our biotech clients, and ensures data integrity, speed, and compliance across multisite and global studies.
"Our seven Avance Clinical accredited Medidata experts lead our efforts, and it makes a real difference for our clients having them inhouse rather than as external consultants."
Contact us about your next study. https://www.avancecro.com/eclinical-solutions/
About Avance Clinical - www.avancecro.com
Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations. Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field. Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups.
Other benefits include: 1. The Government R&D grant means up to 43.5% rebate on clinical trial spend 2. eClinical solutions - speed and continuity 3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks 4. No IND required for clinical trials 5. Full GMP material is not mandated for Phase I clinical trials 6. Established clinical trial environment with world-class Investigators and sites 7. Established healthy subject databases and specialized patient populations 8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care 9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research 10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons
About Medidata - www.medidata.com
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,600+ customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systemes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life Sciences™.
Medidata is a registered trademark of Medidata Solutions, Inc., a wholly-owned subsidiary of Dassault Systemes.
About Dassault Systemes - www.3ds.com
Dassault Systemes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual experience twins of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systemes brings value to more than 290,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.
3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, EXALEAD, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systemes, a French "societe europeenne" (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.
Media Contact: Chris Thompson media@avancecro.com
Koh Shu Mei shumei.koh@omnicomprgroup
Source: Avance Clinical Sectors: Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
Mitsubishi Motors Cumulative Production Reaches One Million Units in Indonesia Dec 20, 2024 17:35 JST
| Contract Renewed on Operation and Maintenance (O&M) Services for APM System at Washington Dulles International Airport Dec 20, 2024 17:24 JST
| Toyota Launches Alphard and Vellfire PHEV Models in Japan Dec 20, 2024 15:38 JST
| 6G Begins! Embarking on a New Journey of Global Interoperable Standards Dec 19, 2024 16:50 JST
| MI LNG Company to Change Corporate Name to MILES Dec 19, 2024 13:49 JST
| Two Honda 0 Series Prototype Models to Premiere at CES 2025 Dec 19, 2024 12:30 JST
| Honda Presents World Premiere of Honda S+ Shift, Next-generation e:HEV Technology Dec 19, 2024 12:13 JST
| NEC Completes new Asia Pacific submarine cable Dec 19, 2024 12:02 JST
| Enablement of JCB Contactless Payment at All NJ TRANSIT Contactless Bus and Light Rail Validators in New Jersey, New York, and Pennsylvania Dec 19, 2024 12:00 JST
| Honda Presents Next-generation e:HEV Technologies at Press Briefing on Honda e:HEV Business and Technology Dec 18, 2024 17:50 JST
| MHI Appoints CTO Eisaku Ito as Next President & CEO, Announces Changes in Board and Executive-level Personnel Dec 18, 2024 17:38 JST
| Honda to Utilize Existing Powertrain Unit Factory to Establish New Production Plant for Next-generation Fuel Cell System in Japan Dec 18, 2024 17:22 JST
| NEC Receives Telecom Review's Global Excellence Award for Innovative Telecom B2B/ Enterprise Network Solutions Dec 18, 2024 17:12 JST
| Japan's Telecommunications Carriers Join Forces to Strengthen Disaster Response Dec 18, 2024 16:11 JST
| Toyota's Fuel Cell and Water Electrolysis System Production Plan Certified as a METI Support Program for Building GX Supply Chains Dec 18, 2024 13:51 JST
| DENSO and onsemi Collaborate for a Strengthened Relationship Dec 17, 2024 14:26 JST
| Asian Financial Forum returns as Region's First Major International Financial Assembly in 2025 Dec 17, 2024 13:44 JST
| Fujitsu recognized as Leader in IDC MarketScape: Worldwide Digital Workplace Services 2024 Vendor Assessment Dec 16, 2024 10:20 JST
| MHI Group Issues its "SUSTAINABILITY DATABOOK 2024" Dec 13, 2024 16:31 JST
| Notification of Dissolution of Joint Management of LT Metal Co., Ltd. by TANAKA Kikinzoku Kogyo K.K. and LT Corp. Dec 13, 2024 04:00 JST
|
More Latest Release >>
|